Company profile
STIMALIA
Restoring Calm, Reclaiming Lives: Minimally Invasive Bioelectronic Therapy for PTSD
- Industry
- Medical Equipment Manufacturing
- Employees
- 7
- Headquarters
- Louvain La Neuve
- Founded
- 2025
- Office locations
- 1
STIMALIA company summary
STIMALIA is a company in the Medical Equipment Manufacturing industry, headquartered in Louvain La Neuve, founded in 2025. On LinkedIn the company has around 7 employees. Its listed specialties include Psychiatry, Mental Health, PTSD.
What technology does STIMALIA use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About STIMALIA
Restoring Calm. Reclaiming Lives. Stimalia develops the first bioelectronic medical device for PTSD, transforming trauma care through minimally invasive neuromodulation that directly addresses the body's dysregulated stress response. The Crisis PTSD affects 24 million adults across Europe and the US, costing €350 billion annually. Over 50% remain symptomatic despite current therapies. Medications cause systemic side effects. Psychotherapy is time-intensive. Nerve blocks fade within weeks. Patients suffer persistent disability, opioid dependence, and elevated suicide risk. Our Innovation We've engineered a revolutionary grain-of-rice-sized, battery-free percutaneous bioelectronic implant. Wirelessly activated, it delivers sustained inhibition of pathological sympathetic hyperactivity, the nervous system overdrive driving PTSD symptoms. Unlike temporary nerve blocks, our approach provides continuous, adjustable, fully reversible therapy without surgery, leads, or systemic side effects. Why It Works Built on proven clinical evidence: 70-80% responder rates from stellate ganglion block studies, Level-I RCT validation, and real-world effectiveness across 1,293 patients. We're translating that proven mechanism into durable, patient-centric bioelectronic therapy and category disruption in PTSD treatment. Market Opportunity €2.3 billion PTSD therapy market. Platform extends to chronic pain and autonomic dysfunction, unlocking €15 billion peripheral neuromodulation opportunity. Our Team Founded by neuromodulation pioneer Pascal Doguet, PhD (CTO; 300+ patents), MedTech entrepreneur Olivier Ménage, PharmD (CEO; 25+ years), and neurovascular expert Sylvain d'Amico, MSc (CCO; Boston Scientific, Stryker, Penumbra). Supported by world-class scientific advisors.
Specialties
Where is STIMALIA located?
STIMALIA lists 1 location.
Compare companies similar to STIMALIA
More companies in Medical Equipment Manufacturing.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
STIMALIA stimalia.com | Medical Equipment Manufacturing | 7 | 2025 | Louvain La Neuve |
 Boston Scientific bostonscientific.com | Medical Equipment Manufacturing | 54,970 | - | Marlborough, MA |
 BD bd.com | Medical Equipment Manufacturing | 46,224 | - | Franklin Lakes, New Jersey |
 Baxter International Inc. baxter.com | Medical Equipment Manufacturing | 39,218 | - | Deerfield, Illinois |
 Alcon alcon.com | Medical Equipment Manufacturing | 27,667 | - | Geneva, Switzerland |
 Smith+Nephew smith-nephew.com | Medical Equipment Manufacturing | 19,271 | - | Watford, Hertfordshire, GB |
 Zimmer Biomet EMEA zimmerbiomet.com | Medical Equipment Manufacturing | 19,125 | - | Warsaw, Indiana |
 Olympus Corporation olympus-global.com | Medical Equipment Manufacturing | 13,703 | 1919 | Shinjuku-ku, Tokyo |
 Intuitive intuitive.com | Medical Equipment Manufacturing | 13,091 | 1995 | California, 94086 |
 Medline Australia medline.com | Medical Equipment Manufacturing | 18,899 | - | Northfield, IL |
 Edwards Lifesciences edwards.com | Medical Equipment Manufacturing | 14,197 | 1958 | Irvine, CA |
Frequently asked questions about STIMALIA
What does STIMALIA do?
Restoring Calm. Reclaiming Lives. Stimalia develops the first bioelectronic medical device for PTSD, transforming trauma care through minimally invasive neuromodulation that directly addresses the body's dysregulated stress response. The Crisis PTSD affects 24 million adults across Europe and the US, costing €350 billion annually. Over 50% remain symptomatic despite current therapies. Medications cause systemic side effects. Psychotherapy is time-intensive. Nerve blocks fade within weeks. Patients suffer persistent disability, opioid dependence, and elevated suicide risk. Our Innovation We've engineered a revolutionary grain-of-rice-sized, battery-free percutaneous bioelectronic implant. Wirelessly activated, it delivers sustained inhibition of pathological sympathetic hyperactivity, the nervous system overdrive driving PTSD symptoms. Unlike temporary nerve blocks, our approach provides continuous, adjustable, fully reversible therapy without surgery, leads, or systemic side effects. Why It Works Built on proven clinical evidence: 70-80% responder rates from stellate ganglion block studies, Level-I RCT validation, and real-world effectiveness across 1,293 patients. We're translating that proven mechanism into durable, patient-centric bioelectronic therapy and category disruption in PTSD treatment. Market Opportunity €2.3 billion PTSD therapy market. Platform extends to chronic pain and autonomic dysfunction, unlocking €15 billion peripheral neuromodulation opportunity. Our Team Founded by neuromodulation pioneer Pascal Doguet, PhD (CTO; 300+ patents), MedTech entrepreneur Olivier Ménage, PharmD (CEO; 25+ years), and neurovascular expert Sylvain d'Amico, MSc (CCO; Boston Scientific, Stryker, Penumbra). Supported by world-class scientific advisors.
How many employees does STIMALIA have?
STIMALIA has around 7 employees on LinkedIn.
Where is STIMALIA headquartered?
STIMALIA is headquartered in Louvain La Neuve.
When was STIMALIA founded?
STIMALIA was founded in 2025.
Build a lead list from companies like STIMALIA
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.